Bristol Myers price target raised to $60 from $54 at Leerink

Core Viewpoint - Leerink analyst David Risinger has raised the price target for Bristol Myers (BMY) to $60 from $54, maintaining an Outperform rating, indicating confidence in the company's future performance and pipeline potential [1]. Group 1: Pipeline Potential - The firm sees significant pipeline optionality in 2026, suggesting that there is room for additional stock upside potential based on upcoming developments [1]. - Bristol Myers is expected to have 12 registrational data readouts from 8 assets in 2026, which represent significant new launch opportunities in the coming years [1]. - The firm believes that investors are heavily discounting most pipeline candidates, indicating that positive outcomes could lead to substantial upside for the stock [1].